Design Therapeutics (DSGN) Interest Expenses (2020 - 2026)
Design Therapeutics (DSGN) posted quarterly Interest Expenses of $3.2 million for Q2 2026, up 17.56% year-over-year from $2.7 million in Q2 2025, and down 4.05% on a QoQ basis from $3.4 million in Q1 2026.
Design Therapeutics (DSGN) Interest Expenses (2020 - 2026) Analysis & Trends
Design Therapeutics has reported Interest Expenses for 7 years, with the latest figure at $3.2 million in Q2 2026.
- Interest Expenses for Q2 2026 came in at $3.2 million, up 17.56% year-over-year; the trailing twelve-month figure through Jun 2026 was $10.4 million (up 2.2% YoY), and the FY2025 annual result was $53.7 billion, up 173.41% from the prior year.
- Interest Expenses fell to $3.2 million in Q2 2026, from $3.4 million in the prior quarter.
- Over five years, Interest Expenses peaked at $10.5 billion in Q4 2022 and troughed at $2.2 million in Q4 2025.
- A 5-year average of $590.4 million and a median of $3.3 million in 2026 frame the typical range for Interest Expenses.
- The widest annual swing landed in 2023, when Interest Expenses sank 99.6%; it then jumped 32.07% in 2026.
- A 5-year view of Interest Expenses shows it stood at $10.5 billion in 2022, then sank by 99.6% to $42.4 million in 2023, then tumbled by 93.79% to $2.6 million in 2024, then slipped by 17.1% to $2.2 million in 2025, then soared by 47.3% to $3.2 million in 2026.
- Per Business Quant data, the three most recent Interest Expenses figures were $3.2 million in Q2 2026, $3.4 million in Q1 2026, and $2.2 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Design Therapeutics | 928.06 Mn | 720.67 Mn | - | 3.22 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.22 Mn |
| Jun 30, 2026 | 3.22 Mn |
| Mar 31, 2026 | 3.36 Mn |
| Mar 31, 2026 | 3.36 Mn |
| Dec 31, 2025 | 2.19 Mn |
| Dec 31, 2025 | 2.19 Mn |
| Sep 30, 2025 | 2.27 Mn |
| Sep 30, 2025 | 2.27 Mn |
| Jun 30, 2025 | 2.74 Mn |
| Jun 30, 2025 | 2.74 Mn |
| Mar 31, 2025 | 2.54 Mn |
| Mar 31, 2025 | 2.54 Mn |
| Dec 31, 2024 | 2.64 Mn |
| Dec 31, 2024 | 2.64 Mn |
| Sep 30, 2024 | 2.27 Mn |
| Sep 30, 2024 | 2.27 Mn |
| Jun 30, 2024 | 2.21 Mn |
| Jun 30, 2024 | 2.21 Mn |
| Mar 31, 2024 | 2.19 Mn |
| Mar 31, 2024 | 2.19 Mn |